Accéder au contenu
Merck

Thalamic stimulation to improve level of consciousness after seizures: evaluation of electrophysiology and behavior.

Epilepsia (2014-12-03)
Abhijeet Gummadavelli, Joshua E Motelow, Nicholas Smith, Qiong Zhan, Nicholas D Schiff, Hal Blumenfeld
RÉSUMÉ

Understanding the neural mechanisms that support human consciousness is an important frontier in neuroscience and medicine. We previously developed a rodent model of temporal lobe seizures that recapitulates the human electroencephalography (EEG) signature of ictal and postictal neocortical slow waves associated with behavioral impairments in level of consciousness. The mechanism of slow-wave production in epilepsy may involve suppression of the subcortical arousal systems including the brainstem and intralaminar thalamic nuclei. We hypothesized that intralaminar thalamic stimulation may lead to electrophysiologic and functional rescue from postictal slow waves and behavioral arrest. We electrically stimulated the central lateral thalamic nucleus (a member of the intralaminar nuclei) under anesthesia and after electrically induced hippocampal seizures in anesthetized and in awake-behaving animal model preparations. We demonstrated a proof-of-principle restoration of electrophysiologic and behavioral measures of consciousness by stimulating the intralaminar thalamic nuclei after seizures. We measured decreased cortical slow waves and increased desynchronization and multiunit activity in the cortex with thalamic stimulation following seizures. Functionally, thalamic stimulation produced resumption of exploratory behaviors in the postictal state. Targeting of nodes in the neural circuitry of consciousness has important medical implications. Impaired consciousness with epilepsy has dangerous consequences including decreased school/work performance, social stigmatization, and impaired airway protection. These data suggest a novel therapeutic approach for restoring consciousness after seizures. If paired with responsive neurostimulation, this may allow rapid implementation to improve level of consciousness in patients with epilepsy.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
11-Mercaptoundecanoic acid, 95%
Sigma-Aldrich
Xylazine, ≥99%
Sigma-Aldrich
11-Mercaptoundecanoic acid, 98%
Sigma-Aldrich
5,5-Diphenylhydantoin sodium salt, ≥99%
USP
Phenytoin sodium, United States Pharmacopeia (USP) Reference Standard
Supelco
Phenytoin sodium, Pharmaceutical Secondary Standard; Certified Reference Material
Phenytoin sodium, European Pharmacopoeia (EP) Reference Standard